Inventiva (NASDAQ:IVA) PT Lowered to $13.00

Inventiva (NASDAQ:IVA) had its target price trimmed by HC Wainwright from $14.00 to $13.00 in a research note published on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Inventiva’s FY2026 earnings at ($2.43) EPS, FY2027 earnings at ($3.06) EPS and FY2028 earnings at $1.20 EPS.

Separately, Stifel Nicolaus dropped their price objective on Inventiva from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, September 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $16.25.

Inventiva Stock Performance

NASDAQ:IVA opened at $2.63 on Tuesday. The stock’s 50 day moving average price is $2.17 and its two-hundred day moving average price is $2.78. Inventiva has a 12-month low of $1.53 and a 12-month high of $4.75.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC bought a new position in shares of Inventiva S.A. (NASDAQ:IVA) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is currently owned by institutional investors.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.